BRAIN PATHOLOGY, published by WILEY, is a leading journal in the fields of neurology, neuroscience, and pathology, recognized for its rigorous peer-review process and high-impact research contributions. With an impressive impact factor and consistently ranked in the Q1 quartile across multiple categories, BRAIN PATHOLOGY maintains a prominent status, with a Scopus ranking placing it among the top 10% of journals in its fields. Since its inception in 1990, the journal has served as a crucial platform for researchers and clinicians alike, disseminating groundbreaking findings that advance our understanding of brain diseases and injuries. Through its dedication to publishing high-quality, innovative research, BRAIN PATHOLOGY plays a vital role in shaping the future of brain pathology research. While it does not currently offer open access, articles can be accessed through institutional subscriptions. Researchers, professionals, and students are encouraged to contribute to and engage with this esteemed publication to foster knowledge and collaboration within this dynamic field.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

Frontiers in Molecular Neuroscience, published by FRONTIERS MEDIA SA, is an esteemed open-access journal dedicated to advancing our understanding of the molecular mechanisms underlying neurological functions and disorders. Since its inception in 2008, the journal has established itself as a reputable source of cutting-edge research, earning a respectable Q2 ranking in both the fields of Cellular and Molecular Neuroscience and Molecular Biology as of 2023. With an ongoing commitment to fostering innovation, the journal presents a platform for researchers, professionals, and students to disseminate their findings and engage in scholarly discourse. The E-ISSN 1662-5099 ensures that research is readily accessible, facilitating the exchange of knowledge crucial to tackling the complexities of neurological conditions. Situated in Switzerland, the journal’s global reach is augmented by its open-access model, allowing for wide dissemination of critical research findings to a diverse audience. Join the vibrant community of scientists and practitioners who are shaping the future of molecular neuroscience through their contributions to this dynamic journal.

NATURE NEUROSCIENCE is a premier journal published by NATURE PORTFOLIO, focusing on cutting-edge research in the field of neuroscience. With an esteemed impact factor that reflects its significance in the academic community, this journal occupies an exceptional place in the 2023 Q1 category for neuroscience (miscellaneous) and boasts a leading Scopus rank of #1 out of 113 in general neuroscience, placing it within the top 1st percentile. Since its inception in 1998, NATURE NEUROSCIENCE has consistently delivered high-quality, peer-reviewed articles that contribute to our understanding of the nervous system, driving innovation and scholarship across disciplines. Although it does not offer open access, the journal remains a vital resource for researchers, professionals, and students seeking to stay at the forefront of neuroscientific discovery and discussion. Its editorial commitment to excellence ensures that it continually shapes the trajectory of neuroscience research well into 2024 and beyond, making it an indispensable asset for anyone passionate about the brain and its complexities.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

CELL is a premier academic journal in the field of Biochemistry, Genetics, and Molecular Biology, published by CELL PRESS. Founded in 1974, this esteemed journal has steadfastly contributed to advancing our understanding of cellular processes and organisms, making it integral for researchers and practitioners alike. With an impressive impact factor that places it in the Q1 category of its field, CELL ranks #1 out of 221 in general biochemistry and genetics, achieving a remarkable 99th percentile in Scopus rankings. Though it is not currently an open-access publication, the journal regularly disseminates high-quality research that impacts the scientific community significantly. Researchers, students, and professionals seeking to stay at the forefront of innovative discoveries and methodologies in molecular biology will find CELL an invaluable resource through its comprehensive articles and reviews.

CLINICAL NEUROPATHOLOGY is a vital scholarly journal published by DUSTRI-VERLAG DR KARL FEISTLE, specializing in the domains of neurology, pathology, and their clinical applications. Established in 1982 and spanning through to its projected completion in 2024, this journal disseminates high-quality research that significantly contributes to the understanding of neurological disorders and their pathological underpinnings. While the journal currently operates under a traditional access model, its commitment to rigorous peer review ensures the publication of impactful findings, strengthening its foothold in the field, as evidenced by its Q3 quartile rankings in several categories, including Medicine (miscellaneous), Neurology, and Pathology and Forensic Medicine. Those engaged in clinical research and practice will find CLINICAL NEUROPATHOLOGY to be an essential resource for the latest advancements, trends, and discussions that shape the future of neurological pathology.

ASN Neuro is an esteemed academic journal published by Frontiers Media SA, focusing on critical advancements in the fields of neurology and neuroscience. Since its inception in 2009, it has established itself as an Open Access platform dedicated to fostering the dissemination of knowledge and research findings that address the complexities of the nervous system. With an impressive impact factor and consistently ranking in the top quartiles of its categories—Q1 in Neurology (clinical) and Q2 in Neuroscience (miscellaneous)—ASN Neuro is recognized for its high-quality publications that cater to the evolving challenges in clinical neurology and general neuroscience. Currently, it ranks 68th out of 400 journals in Clinical Neurology and 28th out of 113 in General Neuroscience, affirming its reputable position within the academic community. Researchers, professionals, and students alike are encouraged to contribute to and benefit from this impactful journal as it presents a unique opportunity to engage with cutting-edge research, innovative methodologies, and insightful reviews in the ever-evolving landscape of brain science.

NEUROPATHOLOGY, an esteemed journal published by WILEY, is a pivotal platform in the fields of medicine and neurology, focusing on the intricate relationship between pathology and neurological disorders. Established in 1993 and continually evolving until 2024, the journal holds a notable presence within the academic community, as evidenced by its current Q2 ranking in several categories including Medicine (Miscellaneous), Neurology (Clinical), and Pathology and Forensic Medicine. With a Scopus ranking placing it within the top 30% of its field, NEUROPATHOLOGY serves as a vital resource for researchers, healthcare professionals, and students dedicated to advancing their knowledge of neuropathological processes. Although not an Open Access journal, it ensures accessibility to cutting-edge research and insights that shape contemporary understanding and clinical practice. Its robust impact factor underscores the journal's critical role in disseminating innovative findings within the realms of neurology and pathology, making it an essential read for those at the forefront of medical research.

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.